SHILPA MEDICARE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 545.5 INR | +2.86% |
|
+2.05% | +65.10% |
| Apr. 18 | Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US | MT |
| Apr. 17 | Shilpa Medicare Gets GMP Certification from Austrian Agency for Telangana, India Unit | MT |
Valuation
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 37,259 | 27,735 | 19,933 | 27,214 | 34,473 | 19,908 |
| Enterprise Value (EV) 1 | 37,238 | 29,335 | 23,410 | 34,445 | 41,053 | 27,699 |
| P/E ratio | 35.6 x | 24.7 x | 12.8 x | 18.4 x | 54.7 x | -61.3 x |
| Yield | 0.15% | 0.29% | 0.45% | 0.33% | 0.28% | - |
| Capitalization / Revenue | 4.72 x | 3.78 x | 2.19 x | 3.02 x | 3.01 x | 1.89 x |
| EV / Revenue | 4.72 x | 4 x | 2.58 x | 3.82 x | 3.58 x | 2.63 x |
| EV / EBITDA | 24.7 x | 19 x | 10.9 x | 20.2 x | 20.7 x | 32 x |
| EV / FCF | -38.1 x | -13.1 x | -10.5 x | -8.55 x | -17.5 x | -25.1 x |
| FCF Yield | -2.63% | -7.62% | -9.56% | -11.7% | -5.72% | -3.98% |
| Price to Book | 3.49 x | 2.32 x | 1.5 x | 1.84 x | 1.89 x | 1.12 x |
| Nbr of stocks (in thousands) | 80,127 | 81,527 | 81,527 | 81,527 | 86,802 | 86,802 |
| Reference price 2 | 465.0 | 340.2 | 244.5 | 333.8 | 397.2 | 229.4 |
| Announcement Date | 8/28/18 | 8/29/19 | 8/15/20 | 9/4/21 | 9/5/22 | 9/5/23 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: März | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 7,894 | 7,337 | 9,082 | 9,016 | 11,469 | 10,517 |
| EBITDA 1 | 1,509 | 1,545 | 2,144 | 1,709 | 1,981 | 865.4 |
| EBIT 1 | 1,148 | 1,141 | 1,723 | 1,188 | 1,204 | -54 |
| Operating Margin | 14.54% | 15.55% | 18.97% | 13.17% | 10.5% | -0.51% |
| Earnings before Tax (EBT) 1 | 1,368 | 1,357 | 1,881 | 1,951 | 1,023 | -382.8 |
| Net income 1 | 1,052 | 1,123 | 1,562 | 1,478 | 606.6 | -324.8 |
| Net margin | 13.33% | 15.3% | 17.19% | 16.39% | 5.29% | -3.09% |
| EPS 2 | 13.07 | 13.77 | 19.15 | 18.13 | 7.260 | -3.741 |
| Free Cash Flow 1 | -978.2 | -2,234 | -2,238 | -4,028 | -2,348 | -1,104 |
| FCF margin | -12.39% | -30.46% | -24.64% | -44.67% | -20.47% | -10.5% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | 0.7000 | 1.000 | 1.100 | 1.100 | 1.100 | - |
| Announcement Date | 8/28/18 | 8/29/19 | 8/15/20 | 9/4/21 | 9/5/22 | 9/5/23 |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,912 | 2,080 | 2,374 | 2,953 | 2,723 | 3,406 | 2,612 | 2,629 | 2,625 |
| EBITDA 1 | 209.7 | 262.5 | 318.8 | 531.6 | 450.9 | 737.3 | 205.7 | 122 | 312.9 |
| EBIT | - | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/13/21 | 5/31/21 | 8/14/21 | 10/29/21 | 2/8/22 | 5/23/22 | 8/11/22 | 11/11/22 | 2/14/23 |
1INR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 1,599 | 3,477 | 7,231 | 6,579 | 7,791 |
| Net Cash position 1 | 21.2 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 1.035 x | 1.622 x | 4.23 x | 3.322 x | 9.002 x |
| Free Cash Flow 1 | -978 | -2,234 | -2,238 | -4,028 | -2,348 | -1,104 |
| ROE (net income / shareholders' equity) | 9.97% | 9.65% | 12.3% | 10.5% | 3.7% | -1.72% |
| ROA (Net income/ Total Assets) | 4.78% | 4.59% | 5.99% | 3.21% | 2.73% | -0.12% |
| Assets 1 | 22,039 | 24,478 | 26,072 | 46,059 | 22,200 | 278,051 |
| Book Value Per Share 2 | 133.0 | 147.0 | 163.0 | 181.0 | 210.0 | 205.0 |
| Cash Flow per Share 2 | 9.030 | 4.200 | 5.440 | 15.10 | 3.900 | 2.460 |
| Capex 1 | 1,380 | 3,000 | 3,493 | 3,542 | 3,318 | 2,725 |
| Capex / Sales | 17.48% | 40.89% | 38.46% | 39.29% | 28.93% | 25.91% |
| Announcement Date | 8/28/18 | 8/29/19 | 8/15/20 | 9/4/21 | 9/5/22 | 9/5/23 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +65.10% | 568M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- SHILPAMED Stock
- Financials Shilpa Medicare Limited
